Histogenics Corporation (NASDAQ:HSGX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, September 7th. The brokerage presently has a $2.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective indicates a potential downside of 3.85% from the stock’s current price.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
Several other research analysts have also recently commented on HSGX. Canaccord Genuity reiterated a “buy” rating on shares of Histogenics Corporation in a report on Thursday, May 11th. HC Wainwright set a $4.00 price target on shares of Histogenics Corporation and gave the stock a “buy” rating in a report on Saturday, May 13th. Finally, ValuEngine upgraded shares of Histogenics Corporation from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $5.25.
Shares of Histogenics Corporation (NASDAQ:HSGX) traded down 0.95% during midday trading on Thursday, hitting $2.08. The company had a trading volume of 176,605 shares. The firm’s market capitalization is $46.78 million. Histogenics Corporation has a 1-year low of $1.45 and a 1-year high of $3.56. The stock has a 50 day moving average price of $1.85 and a 200 day moving average price of $1.77.
Histogenics Corporation (NASDAQ:HSGX) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.06. During the same quarter in the previous year, the company earned ($0.61) EPS. On average, equities analysts anticipate that Histogenics Corporation will post ($1.09) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Histogenics Corporation (NASDAQ:HSGX) Stock Rating Upgraded by Zacks Investment Research” was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.truebluetribune.com/2017/09/17/histogenics-corporation-hsgx-lifted-to-buy-at-zacks-investment-research-2.html.
A hedge fund recently raised its stake in Histogenics Corporation stock. Sabby Management LLC grew its stake in Histogenics Corporation (NASDAQ:HSGX) by 15.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,095,422 shares of the biotechnology company’s stock after buying an additional 150,531 shares during the period. Sabby Management LLC owned 5.31% of Histogenics Corporation worth $1,895,000 at the end of the most recent reporting period. Institutional investors own 50.08% of the company’s stock.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.